A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Condition: Lymphoma, Non-Hodgkin · Lymphoma, B-Cell · Lymphoma, Large B-Cell, Diffuse · Sponsor: Janssen Research & Development, LLC
About this study
This is a Phase 1b/2, multicenter, open-label, study of JNJ-90014496, an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for the treatment of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (32)
| City of Hope | Duarte, California, United States | — |
| Colorado Blood Cancer Institute | Denver, Colorado, United States | — |
| University of Iowa Hospital and Clinics | Iowa City, Iowa, United States | — |
| University of Kentucky Medical Center | Lexington, Kentucky, United States | — |
| Rutgers Cancer Institute of New Jersey | Piscataway, New Jersey, United States | — |
| Levine Cancer Institute | Charlotte, North Carolina, United States | — |
| University Hospitals Cleveland Medical Center | Cleveland, Ohio, United States | — |
| University of Pittsburgh Medical Center | Pittsburgh, Pennsylvania, United States | — |
| Greco Hainesworth Tennessee Oncology Centers for Research | Nashville, Tennessee, United States | — |
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | — |
| St. David's South Austin Medical Center | Austin, Texas, United States | — |
| MD Anderson Cancer Center | Houston, Texas, United States | — |
+ 20 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05421663